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in a Trauma Patient: Case Report
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ABSTRACT
This case report describes a complex trauma patient who develops
hyperkalemia secondary to heparin. Heparin is a commonly used drug in
trauma patients. Physicians need to be aware of this potentially harmful adverse
reaction in these high-risk patients.

Author affiliations are
listed at the end of this
article.
Correspondence to:

Errington C. Thompson, MD

Marshall University
Joan C. Edwards
School of Medicine

thompsoner@marshall.edu

KEYWORDS

Trauma, Heparin, Anticoagulation, Hyperkalemia, Critical Care, Renal Insufficiency

INTRODUCTION
Deep venous thrombosis (DVT) is a serious potential
complication of trauma. In his classic article, Geerts
et al identified risk factors for developing DVT in
trauma patients, with head injuries, spinal cord
injuries, and lower extremity fractures at the highest
risk.1 Prophylactic anticoagulation is recommended
in these high-risk patients.2-4 We present a high-risk
trauma patient who developed a rare complication of
hyperkalemia secondary to heparin.
CASE PRESENTATION
A 47-year-old male was an unrestrained passenger
involved in a rollover motor vehicle crash. The patient
was confused at the scene. Emergency medical
service transported the patient to Cabell Huntington
Hospital. The patient arrived hemodynamically stable
(blood pressure 124/106 mm Hg, pulse 76 beats/
minute, respiratory rate 20 respirations/minute, oral
temperature 98.1ºF). The patient was not moving
his legs, and he underwent multiple computed
tomography (CT) scans – head, cervical spine, chest,
abdominal, and pelvis with reconstructions of the
thoracic and lumbar spines. No intracranial injury
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was identified. The CT of the cervical spine revealed
bilateral jumped facets at C7-T1 with high-grade
spinal stenosis with possible crush injury to the
spinal cord. A fracture of the sternum was seen
on the patient’s chest CT along with a posterior
mediastinal paraspinous hematoma which extended
from T1 to T4. The CT of the abdomen/pelvis revealed
an acetabular fracture as well as an L5 superior
endplate fracture without compromise of the spinal
canal. The kidneys were normal. Admission labs
were unremarkable including a potassium level
of 3.8 mEq/L. The patient’s past medical history
included hypertension and diabetes. The patient also
reportedly had a stroke several years earlier and was
taking aspirin prophylactically. The patient was a one
pack per day smoker.
While in the emergency room, the patient developed
neurogenic shock but responded appropriately
to resuscitative efforts which included fluid and
norepinephrine. He was admitted to the intensive
care unit. Orthopedics and neurosurgery were
consulted. The patient was placed in traction
via a distal femur pin for his acetabular fracture.
The patient was taken to the operating room
by neurosurgery on post-injury day 1 where he
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FIGURE 1. The blue line is the patient’s potassium level. The orange line is the serum creatinine. The blue
shade box represents when the patient was on Lovenox and the orange box is when the patient was on
heparin.
underwent reduction of his C7/T1 jumped facets with
internal fixation. The patient remained intubated
postoperatively.
The patient spiked a fever on post-injury day 2.
He was pan-cultured which revealed communityacquired pneumonia with Haemophilus influenza.
He was treated with broad-spectrum antibiotics
and subsequent, directed de-escalation based on
susceptibility results. However, the patient developed
septic shock in spite of adequate antibiotic coverage
for H. influenza. He stabilized within hours after
receiving a combination of fluids and pressors.
Also, on post-injury day 2, the patient’s creatinine
was within normal limits (0.98 mg/dL) and he was
started on prophylactic enoxaparin as per the
hospital protocol for patients with spinal cord injuries.
However, his renal function deteriorated, and his
creatinine was elevated to 2.32 mg/dL on post-injury
day 6. In spite of adequate blood pressure and no
evidence of hypovolemia, the patient’s creatinine
continued to climb to 2.60 mg/dl. Nephrology was
consulted and a retroperitoneal ultrasound was
performed, which was normal. The patient was
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switched from D51/2 NS to D5W infused at 75 mL/
hr. The cause of his worsening renal function was
thought to be multifactorial relative to shock and
CT contrast dye. The patient was switched from
enoxaparin to 5,000 units of subcutaneous heparin
three times daily.
Simultaneous to the patient’s decline in renal
function, the patient’s respiratory status continued
to deteriorate. Using a lung-protective strategy to
manage the ventilator, the patient was placed on
airway pressure release ventilation (APRV). However,
the patient developed progressive hypoxia in spite
of being on mechanical ventilation. The patient was
pan-cultured for suspected sepsis; all cultures were
negative. The patient became more hypoxic with
tachycardia and hypotension. The patient was not
responsive to fluid challenges and norepinephrine
was started to support the patient’s blood pressure.
Our goal was to maintain a mean arterial pressure
greater than 65 mmHg. The patient was started
on broad-spectrum antibiotics of piperacillintazobactam and linezolid.
On post-injury day 10, a noninvasive cardiac monitor
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was placed on the patient and an echocardiogram
was obtained which revealed an ejection fraction of
60% with no wall motion abnormalities. However,
the patient’s inferior vena cava was dilated with
poor inspiratory collapse. The non-invasive cardiac
monitor revealed a low cardiac index and a
modestly high systemic vascular resistance which
suggested that the patient’s hypotension was
probably secondary to cardiac dysfunction. The
patient became persistently tachycardiac while on
norepinephrine. He was switched to dobutamine
which resolved his tachycardia and increased his
mean arterial pressure to greater than 65 mmHg.
The patient’s respiratory status began to improve,
and the patient’s dobutamine was weaned off. The
patient was fluid overloaded. Furosemide was given
and the patient voided more than six liters of fluid
over two days. The patient’s potassium climbed to
6 mEq/L in spite of conservative measures such as
removing potassium from IV fluids, so insulin and
albuterol were given. Nephrology suggested that
the patient’s subcutaneous heparin be stopped. The
heparin was discontinued and fondaparinux was
started at 2.5 mg subcutaneously (Figure 1). Over
the next ten days, the patient continued to slowly
improve and was switched back to conventional
ventilation. His potassium began to decrease and by
post-injury day 25, it was within the normal range.
The patient did not require dialysis. The patient
underwent a tracheostomy and percutaneously
placed gastrostomy tube without difficulty. The
patient was extubated without problems; he was
alert and interactive. Prior to discharge, he was
tolerating a regular diet and was transferred to a
rehabilitation center on post-injury day 46.
DISCUSSION
In this case report, we present a complex trauma
patient who was involved in a motor vehicle crash.
The patient sustained multiple injuries including a
C7 spinal cord injury, fractured sternum, posterior
mediastinal paraspinous hematoma which extended
from T1 to T4, an acetabular fracture, and an L5
superior endplate fracture without compromise of
the spinal canal. In the ER, he developed neurogenic
shock and required pressors. The patient’s respiratory
status and renal function declined early during
his hospital course. He was originally placed on
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enoxaparin for DVT prophylaxis but was switched
to heparin because of his decreased creatinine
clearance. The patient’s hyperkalemia persisted while
his serum creatinine began to normalize. Heparin
was discontinued and replaced with fondaparinux
2.5 mg subcutaneous. Upon this switch, the patient’s
potassium concentration began to normalize.
The implication of unfractionated heparin in this
patient’s hyperkalemia is supported secondary to
chronological association, resolution upon alteration
of therapy, and the inability to inculpate other
interventions or baseline disease. Additionally,
the persistent elevation of potassium in spite of
repeated potassium-lowering interventions (i.e.,
insulin, albuterol, and furosemide) and the lowering
of potassium in tube feedings add merit to this
claim. A Naranjo Algorithm Adverse Drug Reaction
Probability Score was tabulated at 6, which indicates
the reaction was probable.5 The only limitations
to determine definite causality include failure to
reintroduce the agent to the patient and a lack of
monitoring serum drug concentrations or dosage
adjustments, neither of which have values or
recommendations suggested in the literature.
The appearance of hyperkalemia in our case
implicates heparin as the inciting agent, as a
significant increase in serum potassium occurred
approximately four to seven days after its
introduction, which is similar to that reported in the
literature.6-8 Furthermore, the effect of acute kidney
injury on our patient’s degree of hyperkalemia is
contradicted by the patient’s improvements in serum
creatinine over the same time frame (Figure 1).
Aldosterone synthesis is selectively reduced in
patients treated with heparin, which may be
associated with reduced number and affinity
of adrenal angiotensin II receptors in the zona
glomerulosa, which has been suggested to occur
in as many as 7% of patients.6 Previous reports
indicate that multiple factors are typically present
that exacerbate the relative aldosterone deficiency
and alter the ability of the host to compensate.
This deficiency results in the reduced secretion of
potassium into the lumen of the late distal tubule
and collecting duct with subsequent hyperkalemia.
We switched the patient from enoxaparin to heparin
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as the patient’s renal function began to deteriorate.
The dosing of enoxaparin in patients with renal
dysfunction is complex. A formula based on the
patient’s body weight, sex, and serum creatinine
has been developed.9 We thought the simpler
approach would be to switch the patient to heparin
which has been used safely in trauma patients for
decades. Also, we were uncertain when the patient’s
renal function would stabilize. If we continued
using enoxaparin, we would have been continually
adjusting the patient’s dosing based on imprecise
fluctuations in serum creatinine or repeated anti-Xa
concentrations.
One must consider other possibilities for the
patient’s hyperkalemia. It is possible that this patient
developed a contrast nephropathy. Those typically
occur 24-48 hours after exposure to contrast dye.10
On arrival, as part of his trauma workup, this patient
was exposed to contrast for multiple CT scans,
but for the next several days, after those scans,
the patient’s creatinine actually decreased. The
patient received 100ml of Isovue 370 on the day of
admission as his only dose of intravenous contrast.
The patient’s creatinine was 1.4 mg/dL (0.70 – 1.40
mg/dl) on admission. During the time in question,
when the patient’s creatinine begins to rise, the
patient was not exposed to intravenous contrast
dye within the previous 24-48 hours. This would
eliminate the contrast dye as a possible cause of the
patient’s hyperkalemia.
Rhabdomyolysis is something else that needs to
be considered. The patient had no clinical evidence
of rhabdomyolysis. We did not obtain a creatinine
kinase or a urine myoglobin while the patient
was in the hospital. The patient had no evidence
of compartment syndrome. Also, the patient had
no evidence of adrenal dysfunction during this
hospitalization. When the patient’s creatinine
began to rise as well as his potassium, a random
cortisol level was obtained. It was 24.5 mcg/dL (3.1
– 22.4 mcg/dl). This patient did not have persistent
metabolic acidosis. The patient’s past medical
history of hypertension and diabetes predisposes
him to renal dysfunction. This may have played a
role in the patient’s acute kidney injury as well as his
hyperkalemia. The most likely cause of the patient’s
hyperkalemia is secondary to heparin. The timing
of the rise in serum potassium and the fact that
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his potassium levels began to fall shortly after the
discontinuing of the heparin is highly suggestive that
heparin was the causative agent.
Finally, this trauma patient was hemodynamically
unstable for his first six or seven days in the hospital.
This is unusual. Most trauma patients will stabilize
quickly once the source of the instability is found. We
believe that the combination of the patient’s spinal
cord injury plus his community-acquired pneumonia
caused the patient to vasodilate. Therefore, his
systemic vascular resistance was low. We responded
with fluids and vasoconstrictors which worked well.
The patient’s acute respiratory failure requiring APRV
is confusing. The patient was somewhat overloaded,
but diuresis didn’t promptly improve the patient’s
pulmonary status. The patient was cultured several
times, but we did not grow any new bacteria from
the patient’s lungs.
CONCLUSION
This case demonstrates the relevance of heparinassociated hyperkalemia and a need for the clinician
to thoroughly consider this drug as a cause of
refractory hyperkalemia in the critically ill patient. A
prompt change to alternative agents like the factor
Xa- inhibitors (i.e. fondaparinux) is an important step
to resolve hyperkalemia in trauma patients who are
at high risk for developing DVT.
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